Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Ascierto on Sequencing of Targeted Therapies for Melanoma

Paolo A. Ascierto, MD
Published: Thursday, Jun 29, 2017

Paolo A. Ascierto, MD, National Tumour Institutue “Fondazione G. Pascale,” Unit of Melanoma, Naples, Italy, discusses the sequencing of targeted therapies for patients with melanoma.

There are several clinical trials investigating the sequencing of targeted therapies, explains Ascierto. There is a particular trial looking at the sequencing of the encorafenib and binimetinib combination, nivolumab (Opdivo) and ipilimumab (Yeroy) combination, and a third arm of immunotherapy in between targeted therapy agents.

<<< View more from the European Post-Chicago Meeting
Paolo A. Ascierto, MD, National Tumour Institutue “Fondazione G. Pascale,” Unit of Melanoma, Naples, Italy, discusses the sequencing of targeted therapies for patients with melanoma.

There are several clinical trials investigating the sequencing of targeted therapies, explains Ascierto. There is a particular trial looking at the sequencing of the encorafenib and binimetinib combination, nivolumab (Opdivo) and ipilimumab (Yeroy) combination, and a third arm of immunotherapy in between targeted therapy agents.

<<< View more from the European Post-Chicago Meeting

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Publication Bottom Border
Border Publication
x